Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

BACKGROUND: At present, immune checkpoint inhibitors, such as pembrolizumab, are widely used in the therapy of advanced non-resectable melanoma, as they induce more durable responses than other available treatments. However, the overall response rate does not exceed 50% and, considering the high cos...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Transl Med
Main Authors: Tsur, Neta, Kogan, Yuri, Avizov-Khodak, Evgenia, Vaeth, Désirée, Vogler, Nils, Utikal, Jochen, Lotem, Michal, Agur, Zvia
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2019
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781362/
https://ncbi.nlm.nih.gov/pubmed/31590677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-2081-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker